Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
Biol Methods Protoc ; 8(1): bpad033, 2023.
Article in English | MEDLINE | ID: mdl-38107402

ABSTRACT

The emergence of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) reawakened the need to rapidly understand the molecular etiologies, pandemic potential, and prospective treatments of infectious agents. The lack of existing data on SARS-CoV-2 hampered early attempts to treat severe forms of coronavirus disease-2019 (COVID-19) during the pandemic. This study coupled existing transcriptomic data from severe acute respiratory syndrome-related coronavirus 1 (SARS-CoV-1) lung infection animal studies with crowdsourcing statistical approaches to derive temporal meta-signatures of host responses during early viral accumulation and subsequent clearance stages. Unsupervised and supervised machine learning approaches identified top dysregulated genes and potential biomarkers (e.g. CXCL10, BEX2, and ADM). Temporal meta-signatures revealed distinct gene expression programs with biological implications to a series of host responses underlying sustained Cxcl10 expression and Stat signaling. Cell cycle switched from G1/G0 phase genes, early in infection, to a G2/M gene signature during late infection that correlated with the enrichment of DNA damage response and repair genes. The SARS-CoV-1 meta-signatures were shown to closely emulate human SARS-CoV-2 host responses from emerging RNAseq, single cell, and proteomics data with early monocyte-macrophage activation followed by lymphocyte proliferation. The circulatory hormone adrenomedullin was observed as maximally elevated in elderly patients who died from COVID-19. Stage-specific correlations to compounds with potential to treat COVID-19 and future coronavirus infections were in part validated by a subset of twenty-four that are in clinical trials to treat COVID-19. This study represents a roadmap to leverage existing data in the public domain to derive novel molecular and biological insights and potential treatments to emerging human pathogens.

3.
J Vis Exp ; (147)2019 05 09.
Article in English | MEDLINE | ID: mdl-31132040

ABSTRACT

The goal of this protocol is to detect and quantify protein expression changes in a cell cycle-dependent manner using single cells isolated from the epidermis of mouse skin. There are seven important steps: separation of the epidermis from the dermis, digestion of the epidermis, staining of the epidermal cell populations with cisplatin, sample barcoding, staining with metal tagged antibodies for cell cycle markers and proteins of interest, detection of metal-tagged antibodies by mass cytometry, and the analysis of expression in the various cell cycle phases. The advantage of this approach over histological methods is the potential to assay the expression pattern of >40 different markers in a single cell at different phases of the cell cycle. This approach also allows for the multivariate correlation analysis of protein expression that is more quantifiable than histological/imaging methods. The disadvantage of this protocol is that a suspension of single cells is needed, which results in the loss of location information provided by the staining of tissue sections. This approach may also require the inclusion of additional markers to identify different cell types in crude cell suspensions. The application of this protocol is evident in the analysis of hyperplastic skin disease models. Moreover, this protocol can be adapted for the analysis of specific sub-type of cells (e.g., stem cells) by the addition of lineage-specific antibodies. This protocol can also be adapted for the analysis of skin cells in other experimental species.


Subject(s)
Cell Cycle , Cell Separation/methods , Flow Cytometry/methods , Keratinocytes/cytology , Skin/cytology , Staining and Labeling , Animals , Animals, Newborn , Cell Survival , Cells, Cultured , Ear/anatomy & histology , Epidermal Cells/cytology , Humans , Mice, Inbred C57BL , Stem Cells/cytology
4.
PLoS One ; 11(8): e0161465, 2016.
Article in English | MEDLINE | ID: mdl-27551807

ABSTRACT

Harlequin Ichthyosis is a severe skin disease caused by mutations in the human gene encoding ABCA12. Here, we characterize a novel mutation in intron 29 of the mouse Abca12 gene that leads to the loss of a 5' splice donor site and truncation of the Abca12 RNA transcript. Homozygous mutants of this smooth skin or smsk allele die perinatally with shiny translucent skin, typical of animal models of Harlequin Ichthyosis. Characterization of smsk mutant skin showed that the delivery of glucosylceramides and CORNEODESMOSIN was defective, while ultrastructural analysis revealed abnormal lamellar bodies and the absence of lipid lamellae in smsk epidermis. Unexpectedly, mutant stratum corneum remained intact when subjected to harsh chemical dissociation procedures. Moreover, both KALLIKREIN 5 and -7 were drastically decreased, with retention of desmoplakin in mutant SC. In cultured wild type keratinocytes, both KALLIKREIN 5 and -7 colocalized with ceramide metabolites following calcium-induced differentiation. Reducing the intracellular levels of glucosylceramide with a glucosylceramide synthase inhibitor resulted in decreased secretion of KALLIKREIN proteases by wild type keratinocytes, but not by smsk mutant keratinocytes. Together, these findings suggest an essential role for ABCA12 in transferring not only lipids, which are required for the formation of multilamellar structures in the stratum corneum, but also proteolytic enzymes that are required for normal desquamation. Smsk mutant mice recapitulate many of the pathological features of HI and can be used to explore novel topical therapies against a potentially lethal and debilitating neonatal disease.


Subject(s)
ATP-Binding Cassette Transporters/genetics , Ichthyosis, Lamellar/genetics , Ichthyosis, Lamellar/pathology , Phenotype , Skin/metabolism , Skin/pathology , Alleles , Animals , Base Sequence , Ceramides/metabolism , Chromosome Mapping , Desmosomes/metabolism , Disease Models, Animal , Epidermis/metabolism , Epidermis/pathology , Epidermis/ultrastructure , Exons , Genes, Recessive , Glucosylceramides/metabolism , Ichthyosis, Lamellar/therapy , Kallikreins/metabolism , Keratinocytes/metabolism , Mice , Models, Biological , Mutation , Permeability , Sequence Analysis, DNA , Skin/ultrastructure , Skin Transplantation
5.
Elife ; 42015 Jul 23.
Article in English | MEDLINE | ID: mdl-26203562

ABSTRACT

In many mouse models of skin cancer, only a few tumors typically form even though many cells competent for tumorigenesis receive the same oncogenic stimuli. These observations suggest an active selection process for tumor-initiating cells. Here, we use quantitative mRNA- and miR-Seq to determine the impact of Hras(G12V) on the transcriptome of keratinocytes. We discover that microRNA-203 is downregulated by Hras(G12V). Using a knockout mouse model, we demonstrate that loss of microRNA-203 promotes selection and expansion of tumor-initiating cells. Conversely, restoration of microRNA-203 using an inducible model potently inhibits proliferation of these cells. We comprehensively identify microRNA-203 targets required for Hras-initiated tumorigenesis. These targets include critical regulators of the Ras pathway and essential genes required for cell division. This study establishes a role for the loss of microRNA-203 in promoting selection and expansion of Hras mutated cells and identifies a mechanism through which microRNA-203 antagonizes Hras-mediated tumorigenesis.


Subject(s)
Cell Proliferation , Gene Expression Regulation , Keratinocytes/physiology , MicroRNAs/metabolism , Neoplastic Stem Cells/physiology , Proto-Oncogene Proteins p21(ras)/metabolism , Animals , Cells, Cultured , Disease Models, Animal , Gene Expression Profiling , Mice, Knockout , Skin Neoplasms/pathology
6.
Cancer Epidemiol Biomarkers Prev ; 23(12): 2829-39, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25410285

ABSTRACT

BACKGROUND: Melanocytic nevi (moles) and freckles are well known biomarkers of melanoma risk, and they are influenced by similar UV light exposures and genetic susceptibilities to those that increase melanoma risk. Nevertheless, the selective interactions between UV exposures and nevus and freckling genes remain largely undescribed. METHODS: We conducted a longitudinal study from ages 6 through 10 years in 477 Colorado children who had annual information collected for sun exposure, sun protection behaviors, and full body skin exams. MC1R and HERC2/OCA2 rs12913832 were genotyped and linear mixed models were used to identify main and interaction effects. RESULTS: All measures of sun exposure (chronic, sunburns, and waterside vacations) contributed to total nevus counts, and cumulative chronic exposure acted as the major driver of nevus development. Waterside vacations strongly increased total nevus counts in children with rs12913832 blue eye color alleles and facial freckling scores in those with MC1R red hair color variants. Sunburns increased the numbers of larger nevi (≥2 mm) in subjects with certain MC1R and rs12913832 genotypes. CONCLUSIONS: Complex interactions between different UV exposure profiles and genotype combinations determine nevus numbers and size, and the degree of facial freckling. IMPACT: Our findings emphasize the importance of implementing sun-protective behavior in childhood regardless of genetic make-up, although children with particular genetic variants may benefit from specifically targeted preventive measures to counteract their inherent risk of melanoma. Moreover, we demonstrate, for the first time, that longitudinal studies are a highly powered tool to uncover new gene-environment interactions that increase cancer risk.


Subject(s)
Albinism, Oculocutaneous/genetics , Melanosis/genetics , Nevus, Pigmented/genetics , Receptor, Melanocortin, Type 1/genetics , Child , Cohort Studies , Female , Genotype , Humans , Male , Phenotype , Ultraviolet Rays
7.
J Invest Dermatol ; 133(1): 78-86, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22832491

ABSTRACT

Aurora kinase-A (Aurora-A) promotes timely entry into mitosis, centrosome maturation, and formation of bipolar spindles. To address the role of Aurora-A in skin development and homeostasis, we interbred a floxed Aurora-A (Aurora-A(fl)) mouse with the Cre-deleter strain, K14.Cre. Aurora-A(fl/fl);Krt14.Cre (Aurora-A(-/-)) mice died shortly after birth. These mice had translucent skin, and histological evaluation showed that the dorsal skin was very thin and fragile with frank erosions. Although the expression of the basal layer marker keratin 14 and the differentiation marker keratin 1 was evident in Aurora-A(-/-) epidermis, there was a marked reduction in the number of suprabasal layers and basal keratinocytes. Dye exclusion assays also showed defects in barrier function. Unlike wild-type cells, Aurora-A(-/-) basal progenitors were delayed in forming two layers at embryonic day (E)13.5 when embryonic skin begins to stratify. Increased numbers of mitotic cells, apoptotic bodies, and polyploid keratinocytes were evident in Aurora-A(-/-) epidermis, indicating that a deficiency in Aurora-A promotes aberrant mitosis, mitotic slippage, and cell death. Finally, Aurora-A(-/-) keratinocytes displayed centrosomal abnormalities that included centrosomes located at nonapical sites in basal cells. Thus, the deletion of Aurora-A in the developing epidermis alters centrosome function of basal keratinocytes and markedly impairs their ability to divide and stratify.


Subject(s)
Cell Division/physiology , Protein Serine-Threonine Kinases/physiology , Skin/enzymology , Skin/growth & development , Animals , Apoptosis/physiology , Aurora Kinase A , Aurora Kinases , Cell Differentiation/genetics , Cell Differentiation/physiology , Cell Division/genetics , Centrosome/enzymology , Gene Deletion , Keratin-1 , Keratin-14/biosynthesis , Keratinocytes/physiology , Keratins, Hair-Specific/biosynthesis , Mice , Polyploidy , Protein Serine-Threonine Kinases/genetics , Skin/pathology , Stem Cells/physiology
8.
PLoS One ; 7(12): e50810, 2012.
Article in English | MEDLINE | ID: mdl-23251388

ABSTRACT

The ileal lipid binding protein (ilbp) is a cytoplasmic protein that binds bile acids with high affinity. However evidence demonstrating the role of this protein in bile acid transport and homeostasis is missing. We created a mouse strain lacking ilbp (Fabp6(-/-) mice) and assessed the impact of ilbp deficiency on bile acid homeostasis and transport in vivo. Elimination of ilbp increased fecal bile acid excretion (54.2%, P<0.05) in female but not male Fabp6(-/-) mice. The activity of cholesterol 7α-hydroxylase (cyp7a1), the rate-controlling enzyme of the classical bile acid biosynthetic pathway, was significantly increased in female (63.5%, P<0.05) but not in male Fabp6(-/-) mice. The amount of [(3)H]taurocholic acid (TCA) excreted by 24 h after oral administration was 102% (P<0.025) higher for female Fabp6(-/-) mice whereas it was 57.3% (P<0.01) lower for male Fabp6(-/-) mice, compared to wild-type mice. The retained fraction of the [(3)H]TCA localized in the small and large intestines was increased by 22% (P<0.02) and decreased by 62.7% (P<0.01), respectively, in male Fabp6(-/-) mice relative wild-type mice, whereas no changes were seen in female Fabp6(-/-) mice. Mucosal to serosal bile acid transport using everted distal gut sacs was decreased by 74% (P<0.03) in both sexes of Fabp6(-/-) mice as compared to wild-type mice. The results demonstrate that ilbp is involved in the apical to basolateral transport of bile acids in ileal enterocytes, and is vital for the maintenance of bile acid homeostasis in the enterohepatic circulation (EHC) in mice.


Subject(s)
Bile Acids and Salts/metabolism , Enterohepatic Circulation/physiology , Intestinal Absorption/physiology , Intestine, Small/metabolism , Organic Anion Transporters, Sodium-Dependent/metabolism , Symporters/metabolism , Animals , Biological Transport , Enterocytes/metabolism , Female , Liver/metabolism , Male , Mice , Mice, Knockout , Organic Anion Transporters, Sodium-Dependent/genetics , Sex Factors , Symporters/genetics
9.
Stem Cells ; 29(2): 206-16, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21732479

ABSTRACT

Reprogramming somatic cells into an ESC-like state, or induced pluripotent stem (iPS) cells, has emerged as a promising new venue for customized cell therapies. In this study, we performed directed differentiation to assess the ability of murine iPS cells to differentiate into bone, cartilage, and fat in vitro and to maintain an osteoblast phenotype on a scaffold in vitro and in vivo. Embryoid bodies derived from murine iPS cells were cultured in differentiation medium for 8­12 weeks. Differentiation was assessed by lineage-specific morphology, gene expression, histological stain, and immunostaining to detect matrix deposition. After 12 weeks of expansion, iPS-derived osteoblasts were seeded in a gelfoam matrix followed by subcutaneous implantation in syngenic imprinting control region (ICR) mice. Implants were harvested at 12 weeks, histological analyses of cell and mineral and matrix content were performed. Differentiation of iPS cells into mesenchymal lineages of bone, cartilage, and fat was confirmed by morphology and expression of lineage-specific genes. Isolated implants of iPS cell-derived osteoblasts expressed matrices characteristic of bone, including osteocalcin and bone sialoprotein. Implants were also stained with alizarin red and von Kossa, demonstrating mineralization and persistence of an osteoblast phenotype. Recruitment of vasculature and microvascularization of the implant was also detected. Taken together, these data demonstrate functional osteoblast differentiation from iPS cells both in vitro and in vivo and reveal a source of cells, which merit evaluation for their potential uses in orthopedic medicine and understanding of molecular mechanisms of orthopedic disease.


Subject(s)
Calcification, Physiologic , Induced Pluripotent Stem Cells/metabolism , Osteoblasts/metabolism , Osteogenesis/physiology , Animals , Cell Differentiation , Cells, Cultured , Gene Expression Regulation, Developmental , Induced Pluripotent Stem Cells/cytology , Integrin-Binding Sialoprotein/biosynthesis , Mice , Mice, Inbred ICR , Mice, Nude , Osteoblasts/cytology , Osteocalcin/biosynthesis , Phenotype , Tissue Scaffolds
10.
Stem Cells ; 29(4): 725-35, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21312316

ABSTRACT

Tissue-resident mesenchymal stem cells (MSCs) are important regulators of tissue repair or regeneration, fibrosis, inflammation, angiogenesis, and tumor formation. Here, we define a population of resident lung MSCs (luMSCs) that function to regulate the severity of bleomycin injury via modulation of the T-cell response. Bleomycin-induced loss of these endogenous luMSCs and elicited fibrosis (pulmonary fibrosis), inflammation, and pulmonary arterial hypertension (PAH). Replacement of resident stem cells by administration of isolated luMSCs attenuated the bleomycin-associated pathology and mitigated the development of PAH. In addition, luMSC modulated a decrease in numbers of lymphocytes and granulocytes in bronchoalveolar fluid and demonstrated an inhibition of effector T-cell proliferation in vitro. Global gene expression analysis indicated that the luMSCs are a unique stromal population differing from lung fibroblasts in terms of proinflammatory mediators and profibrotic pathways. Our results demonstrate that luMSCs function to protect lung integrity after injury; however, when endogenous MSCs are lost, this function is compromised illustrating the importance of this novel population during lung injury. The definition of this population in vivo in both murine and human pulmonary tissue facilitates the development of a therapeutic strategy directed at the rescue of endogenous cells to facilitate lung repair during injury.


Subject(s)
Bleomycin/adverse effects , Cell Proliferation , Mesenchymal Stem Cells/drug effects , Pulmonary Fibrosis/chemically induced , T-Lymphocytes/cytology , Animals , Bleomycin/pharmacology , Familial Primary Pulmonary Hypertension , Hypertension, Pulmonary/pathology , Lung Injury , Mesenchymal Stem Cells/cytology , Mice , Mice, Inbred C57BL , Polymerase Chain Reaction , Pulmonary Fibrosis/pathology
11.
Pigment Cell Melanoma Res ; 23(6): 781-94, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20849464

ABSTRACT

p53 is the central member of a critical tumor suppressor pathway in virtually all tumor types, where it is silenced mainly by missense mutations. In melanoma, p53 predominantly remains wild type, thus its role has been neglected. To study the effect of p53 on melanocyte function and melanomagenesis, we crossed the 'high-p53'Mdm4+/− mouse to the well-established TP-ras0/+ murine melanoma progression model. After treatment with the carcinogen dimethylbenzanthracene (DMBA), TP-ras0/+ mice on the Mdm4+/− background developed fewer tumors with a delay in the age of onset of melanomas compared to TP-ras0/+ mice. Furthermore, we observed a dramatic decrease in tumor growth, lack of metastasis with increased survival of TP-ras0/+: Mdm4+/− mice. Thus, p53 effectively prevented the conversion of small benign tumors to malignant and metastatic melanoma. p53 activation in cultured primary melanocyte and melanoma cell lines using Nutlin-3, a specific Mdm2 antagonist, supported these findings. Moreover, global gene expression and network analysis of Nutlin-3-treated primary human melanocytes indicated that cell cycle regulation through the p21WAF1/CIP1 signaling network may be the key anti-melanomagenic activity of p53.


Subject(s)
Cell Cycle , Disease Progression , Melanoma/pathology , Nevus/pathology , Skin Neoplasms/pathology , Tumor Suppressor Protein p53/metabolism , 9,10-Dimethyl-1,2-benzanthracene , Animals , Cell Cycle/radiation effects , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Cellular Senescence/drug effects , Clone Cells , Disease Models, Animal , Humans , Imidazoles/pharmacology , Melanocytes/drug effects , Melanocytes/metabolism , Melanocytes/pathology , Melanoma/metabolism , Mice , Mice, Inbred C57BL , Nevus/metabolism , Pigmentation/drug effects , Piperazines/pharmacology , Proto-Oncogene Proteins/metabolism , Skin Neoplasms/metabolism , Staining and Labeling , Survival Analysis , Transcription, Genetic/drug effects , Tumor Suppressor Protein p53/genetics , Ubiquitin-Protein Ligases/metabolism
13.
Cancer Res ; 69(18): 7207-15, 2009 Sep 15.
Article in English | MEDLINE | ID: mdl-19738056

ABSTRACT

Aurora kinase A (Aurora-A) belongs to a highly conserved family of mitotis-regulating serine/threonine kinases implicated in epithelial cancers. Initially we examined Aurora-A expression levels at different stages of human skin cancer. Nuclear Aurora-A was detected in benign lesions and became more diffused but broadly expressed in well and poorly differentiated squamous cell carcinomas (SCC), indicating that Aurora-A deregulation may contribute to SCC development. To mimic the overexpression of Aurora-A observed in human skin cancers, we established a gene-switch mouse model in which the human variant of Aurora-A (Phe31Ile) was expressed in the epidermis upon topical application of the inducer RU486 (Aurora-AGS). Overexpression of Aurora-A alone or in combination with the tumor promoter 12-O-tetradecanoylphorbol 13-acetate (TPA), did not result in SCC formation in Aurora-AGS mice. Moreover, Aurora-A overexpression in naive keratinocytes resulted in spindle defects in vitro and marked cell death in vivo, suggesting that the failure of Aurora-A to initiate tumorigenesis was due to induction of catastrophic cell death. However, Aurora-A overexpression combined with exposure to TPA and the mutagen 7,12-dimethylbenz(a)anthracene accelerated SCC development with greater metastatic activity than control mice, indicating that Aurora-A cannot initiate skin carcinogenesis but rather promotes the malignant conversion of skin papillomas. Further characterization of SCCs revealed centrosome amplification and genomic alterations by array CGH analysis, indicating that Aurora-A overexpression induces a high level of genomic instability that favors the development of aggressive and metastatic tumors. Our findings strongly implicate Aurora-A overexpression in the malignant progression of skin tumors and suggest that Aurora-A may be an important therapeutic target.


Subject(s)
Protein Serine-Threonine Kinases/genetics , Skin Neoplasms/enzymology , Skin Neoplasms/genetics , 9,10-Dimethyl-1,2-benzanthracene , Adult , Animals , Aurora Kinase A , Aurora Kinases , Carcinoma, Squamous Cell/chemically induced , Carcinoma, Squamous Cell/enzymology , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/pathology , Cell Death/physiology , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/metabolism , Genomic Instability , Humans , Keratinocytes/enzymology , Keratinocytes/pathology , Mice , Mice, Transgenic , Papilloma/chemically induced , Papilloma/enzymology , Papilloma/genetics , Papilloma/pathology , Protein Serine-Threonine Kinases/biosynthesis , Skin Neoplasms/chemically induced , Skin Neoplasms/pathology , Spindle Apparatus/enzymology , Spindle Apparatus/pathology
14.
Mol Cell Biol ; 27(22): 7918-34, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17875932

ABSTRACT

EWS/FLI-1 is a chimeric oncogene generated by chromosomal translocation in Ewing tumors, a family of poorly differentiated pediatric tumors arising predominantly in bone but also in soft tissue. The fusion gene combines sequences encoding a strong transactivating domain from the EWS protein with the DNA binding domain of FLI-1, an ETS transcription factor. A related fusion, TLS/ERG, has been found in myeloid leukemia. To determine EWS/FLI-1 function in vivo, we engineered mice with Cre-inducible expression of EWS/FLI-1 from the ubiquitous Rosa26 locus. When crossed with Mx1-cre mice, Cre-mediated activation of EWS/FLI-1 resulted in the rapid development of myeloid/erythroid leukemia characterized by expansion of primitive mononuclear cells causing hepatomegaly, splenomegaly, severe anemia, and death. The disease could be transplanted serially into naïve recipients. Gene expression profiles of primary and transplanted animals were highly similar, suggesting that activation of EWS/FLI-1 was the primary event leading to disease in this model. The Cre-inducible EWS/FLI-1 mouse provides a novel model system to study the contribution of this oncogene to malignant disease in vivo.


Subject(s)
Leukemia, Myeloid/metabolism , Mice, Transgenic , Oncogene Proteins, Fusion/metabolism , Proto-Oncogene Protein c-fli-1/metabolism , Stem Cells , Animals , Cell Line , Cell Proliferation , Chimera , Chromosome Aberrations , GATA1 Transcription Factor/metabolism , Gene Expression Profiling , Leukemia, Myeloid/etiology , Leukemia, Myeloid/genetics , Leukemia, Myeloid/physiopathology , Mice , Mice, Inbred C57BL , Mice, Inbred NOD , Mice, SCID , Neoplasm Transplantation , Oncogene Proteins, Fusion/genetics , Proteins/genetics , Proteins/metabolism , Proto-Oncogene Protein c-fli-1/genetics , RNA, Untranslated , RNA-Binding Protein EWS , Sarcoma, Ewing , Stem Cells/physiology
15.
Cancer Res ; 63(13): 3464-8, 2003 Jul 01.
Article in English | MEDLINE | ID: mdl-12839926

ABSTRACT

The Ewing family of tumors are poorly differentiated pediatric solid tumors arising in bone and soft tissues from an unknown cell of origin. Ewing tumors are molecularly defined by in-frame genomic fusions that combine EWS with one of several ETS genes, most commonly FLI-1. We considered pluripotent marrow-derived stromal cells a likely candidate for the origin of Ewing tumors and assessed the effects of EWS/ETS proteins in this cell background. EWS/ETS expression in marrow-derived stromal cells caused a dramatic change in cellular morphology that was dependent on the presence of the ETS domain and unique to the fusion proteins. EWS/ETS fusion proteins blocked differentiation along osteogenic and adipogenic lineages, consistent with the undifferentiated appearance of Ewing tumors. Inhibition of differentiation may be an important function of EWS/ETS proteins in the genesis of Ewing tumors.


Subject(s)
Bone Marrow Cells/cytology , Cell Differentiation/physiology , Cyclin-Dependent Kinase Inhibitor p16/physiology , Oncogene Proteins, Fusion/physiology , Pluripotent Stem Cells/cytology , Proto-Oncogene Proteins , RNA-Binding Protein EWS/physiology , Sarcoma, Ewing/genetics , Adipocytes/cytology , Animals , Cyclin-Dependent Kinase Inhibitor p16/deficiency , Cyclin-Dependent Kinase Inhibitor p16/genetics , DNA-Binding Proteins/genetics , DNA-Binding Proteins/physiology , Medulloblastoma/genetics , Medulloblastoma/pathology , Mice , Mice, Knockout , Oncogene Proteins/genetics , Oncogene Proteins/physiology , Oncogene Proteins, Fusion/genetics , Polymerase Chain Reaction , Proto-Oncogene Protein c-fli-1 , RNA-Binding Protein EWS/deficiency , RNA-Binding Protein EWS/genetics , Trans-Activators/genetics , Trans-Activators/physiology , Transcription Factors/genetics , Transcription Factors/physiology , Transcriptional Regulator ERG , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...